Generic Drug News and Research

RSS

Generic Drugs are official nonbrand names by which medicines are known. Generic names usually refer to the chemical name of the drug.

Branded drug companies give generics a taste of their own medicine

To defend market share, more branded drug companies today release generic versions of their branded drugs before other generic companies enter the market, according to a study by pharmaceutical intelligence firm, Cutting Edge Information.

6 Apr 2005

Much more money needed to tackle flu virus

The World Health Organisation (WHO) is recommending that governments throughout the world need to set aside 5 per cent of what they spend on influenza vaccines to help get ready for the next big flu epidemic.

4 Apr 2005

Ranbaxy settles NHS generic drug claim

Britain's Department of Health and Ranbaxy (UK) Ltd have jointly announced settlement of the claims brought against Ranbaxy for alleged anti-competitive cartel conduct in connection with the supply to the NHS of generic drugs between 1996 and 2000.

4 Apr 2005

Ranbaxy to appeal injunction against sales of Quinapril

Ranbaxy Laboratories Limited (Ranbaxy) announced today that the U.S. District Court for the District of New Jersey hearing the preliminary injunction motion brought by Pfizer against Teva Pharmaceuticals USA, Inc. (Teva) and Ranbaxy Pharmaceuticals Inc. (RPI) enjoined Teva and RPI from selling RPI's quinapril tablets (5, 10, 20, and 40 mg).

30 Mar 2005

Pfizer awarded injunction blocking Teva/Ranbaxy from selling generic Quinapril

Pfizer Inc has obtained a preliminary injunction halting sales of a generic quinapril product marketed by Teva Pharmaceuticals USA Inc., Ranbaxy Pharmaceuticals Inc., and Ranbaxy Laboratories Limited.

30 Mar 2005

India passes the drug Patent Bill

India's parliament passed a new law Wednesday, the Patent (Amendment) Bill, prohibiting the copying of patented drugs, despite strong criticism that the legislation would prohibit the manufacture of low-cost generic drugs.

23 Mar 2005

'Flanking generics' helps pharmas hold market share

Pharmaceutical companies are finding innovative new strategies to retain market share after drug patent expiration. One of the most successful of these new strategies appears to be 'flanking.' Under this strategy, brand-name drug companies sign licensing agreements with their generic competitors to establish manufacturer- distributor relationships.

23 Mar 2005

Ranbaxy files additional Anti-Retroviral (ARV) agents with the World Health Organization

Ranbaxy Laboratories Limited (RLL) announced today that the Company has made two additional filings of its Anti-Retroviral (ARV) agents with the World Health Organization (WHO) for its approval, taking the total number of Ranbaxy ARV filings submitted with the WHO to five.

23 Mar 2005

Indian production of cheap generic drugs could be banned

To ensure India meets World Trade Organisation (WTO) rules on the production of drugs, the Indian Parliament has approved legislation by the parliament's lower house, to ban domestic firms from manufacturing low-cost generic copies of patented drugs.

22 Mar 2005

Are sources of affordable generic medicines drying up?

India should ensure global access to medicines when implementing its patent law.

16 Mar 2005

Cough medicine may cause seizures

Canadian consumers are being advised by Health Canada not to use specific brands of a generic cough syrup that could possibly result in seizures for children under three years of age.

14 Mar 2005

New biocentre which will revolutionise the way future medicines are produced

The University of Manchester has been awarded £6m to open a new biocentre which will revolutionise the way future medicines are produced – making them safer and more effective.

From The University of Manchester 14 Mar 2005

First study to show cost-effectiveness of pre-diabetes intervention

More than 40 million Americans face a high risk of developing Type 2 diabetes, and it would cost a lot to give all of them intensive help with diet and exercise, or medication, to keep them from developing diabetes.

28 Feb 2005

Methylphenidate linked to chromosomal changes

In a small but startling preliminary new study, Texas researchers have found that after just three months, every one of a dozen children treated for attention deficit/hyperactivity disorder (ADHD) with the drug methylphenidate experienced a threefold increase in levels of chromosome abnormalities—occurrences associated with increased risks of cancer and other adverse health effects.

27 Feb 2005

Second-generation Antidepressants

A recent article in the prestigious British Medical Journal seems to confirm an increased risk for suicidal behavior among adults taking popular antidepressants. This follows evidence that certain selective serotonin reuptake inhibitors (SSRIs) may have a similar effect among children and adolescents.

27 Feb 2005

WHO announces $2 billion gap in financing for AIDS treatment

Today, at the Davos World Economic Forum in Switzerland, the World Health Organization (WHO) released a report showing a "rapid expansion" in the number of people living in poor countries gaining access to life-saving AIDS treatment.

26 Jan 2005

Tentative approval of co-packaged lamivudine/zidovudine fixed dose combination tablets and nevirapine tablets

The Food and Drug Administration (FDA) has announced the tentative approval of a co-packaged antiretroviral drug regimen manufactured by Aspen Pharmacare of South Africa for the treatment of HIV-1 infection in adults.

26 Jan 2005

Researchers have identified the cellular receptor for the JC virus

Researchers funded in part by the National Institute of Neurological Disorders and Stroke (NINDS) have identified the cellular receptor for the JC virus, which causes the fatal neurological disease progressive multifocal leukoencephalopathy (PML).

17 Jan 2005

First deceleration in U.S. national health spending growth in seven years

The pace of health spending growth slowed in 2003, marking the first deceleration in national health spending growth in seven years, a report by the Centers for Medicare & Medicaid Services (CMS) Office of the Actuary shows. The annual report is published in the January/February 2005 issue of Health Affairs.

12 Jan 2005

Ranbaxy files anti-retrovirals (ARVs) to the U.S. FDA

Ranbaxy Laboratories Limited (Ranbaxy) announced today that the Company has so far made three filings of its Anti-Retrovirals (ARVs) to the U.S. FDA for its approval under the expedited review process of the President's Emergency Plan for AIDS Relief (PEPFAR).

10 Jan 2005